drugset / Trial / NCT03768375
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Phase 2
Unknown
150 enrolled
Shanghai Jiao Tong University School of Medicine
Eastern Hepatobiliary Surgery Hospital · collabHuashan Hospital · collabRenJi Hospital · collabRuijin Hospital · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Timeline
- Start
- 2016-11
- Primary completion
- 2020-12-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Crizotinib | Small molecule | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Gefitinib | Small molecule | — | — |
| Subject | Lapatinib | Small molecule | — | — |
| Subject | Sorafenib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |